Spots Global Cancer Trial Database for donor lymphocytes
Every month we try and update this database with for donor lymphocytes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma | NCT00006252 | Leukemia Lymphoma | fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt... | - 69 Years | Alliance for Clinical Trials in Oncology | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| AML Therapy With Irradiated Allogeneic Cells | NCT02105116 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Untreated Adult... | fludarabine pho... cytarabine donor lymphocyt... laboratory biom... G-CSF | 18 Years - | Rutgers, The State University of New Jersey | |
| Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | NCT00720447 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cytarabine etoposide melphalan allogeneic bone... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | NCT00923910 | Leukemia, Acute... Leukemia, Acute... Leukemia, Chron... Myelodysplastic... Non-Hodgkin's L... | WT1 Peptide-Pul... Donor Lymphocyt... IL-4 KLH WT1 Peptides Endotoxin Diphenhydramine Acetaminophen | 1 Year - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
